BioWorld-International-2010-02-03

No Abstract

No Abstract

No Abstract

Merus BV, which is developing a novel antibody platform, raised €21.7 million (US$30.3 million) in a Series B round and entered a license option agreement with Novartis AG potentially worth more than $200 million in up-front and milestone payments. (BioWorld International)

No Abstract

No Abstract

No Abstract